Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 6Recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 11Neoplasm Metastasis 7Neoplasms 5Carcinoma, Renal Cell 3Tuberous Sclerosis 2Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Neuroendocrine Tumors 2Leukemia, Myeloid, Acute 2Gastrointestinal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Neuroendocrine 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Sarcoma 1Renal Cell Cancer Metastatic 1Relapsed Pediatric Solid Tumor 1Ovarian Neoplasms 1Osteosarcoma 1Nasopharyngeal Carcinoma 1Metatropic dwarfism 1Melanoma 1Lymphoma 1Liver Neoplasms 1Liver Failure 1Liver Diseases 1Liver Cirrhosis 1Leukemia, Myelomonocytic, Acute 1

Interventions

recombinant interferon alpha 2b-like protein 1lutetium Lu 177 dotatate 1lanreotide 1Sunitinib 1Rose Bengal 1Injections 1Everolimus 1Biological Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Carcinoid Tumor × Everolimus × Clear all
NCT01175096 2010-08-04

Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

Guangdong Provincial People's Hospital

Phase 1/2 Unknown
20 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡